Trial Profile

A Phase I/II, Double-blind, Randomized, Active-controlled, Age De-escalation Trial to Assess Safety and Immunogenicity of a Measles Rubella Vaccine (MRV) Microneedle Patch (MRV-MNP) in Adults, MRV-primed Toddlers, and MRV-naïve Infants

Status: Completed

Phase of Trial: Phase I/II

Latest Information Update: 07 May 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Measles and rubella vaccine microneedle patch Micron Biomedical (Primary) ; Measles and rubella virus vaccine
Indications Measles; Rubella
Focus Adverse reactions
Sponsors Micron Biomedical

29 Apr 2024 Results assessing the tolerability, safety, and immunogenicity of an MRV-MNP in adults, MRV-vaccinated toddlers aged 15-18 months, and MRV-naive infants aged 9-10 months, published in the Lancet.
17 May 2023 According to Micron Biomedical media release,James Goodson is the co-investigator of the study.
17 May 2023 According to Micron Biomedical media release, data from this study were presented at the MICRONEEDLES 2023 conference.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com